Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.

Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: The disclosure provides pharmaceutical formulations of the compound of Formula I: or a pharmaceutically acceptable salt thereof.

Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: Examples of the present disclosure describe systems and methods for passive visit detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from the set of sensors in response to detecting a movement event or user interaction data. The collected sensor data may be processed and provided as input to one or more predictive or statistical models. The model(s) may evaluate the sensor data to detect mobile device location, movement events and visit events. The model(s) may also be used to determine correlations between features of the sensor data and movement- or location-based events, optimize the types of data collected by the set of sensors, extend localized predictions to large-scale ecosystems, and generate battery-efficient state predictions. In aspects, the model(s) may be trained using labeled and/or unlabeled data sets of sensor data.

Abstract: This disclosure relates to systems and methods for passive visit detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from the set of sensors in response to detecting a movement event or user interaction data. The collected sensor data may be processed and provided as input to one or more predictive or statistical models. The model(s) may evaluate the sensor data to detect mobile device location, movement events and visit events. The model(s) may also be used to determine correlations between features of the sensor data and movement- or location-based events, optimize the types of data collected by the set of sensors, extend localized predictions to large-scale ecosystems, and generate battery-efficient state predictions. In aspects, the model(s) may be trained using labeled and/or unlabeled data sets of sensor data.

Abstract: Examples of the present disclosure describe systems and methods for visit detection. More particularly, the described systems and methods relate to improving venue coverage distribution as applied to visit detection models. In aspects, the visit detection system/model of a mobile device may predict that a user is visiting a supervenue based on a set of venue visit probabilities. The visit probability for the supervenue may be redistributed among the subvenues of the supervenue to create a subvenue visit probability distribution. Based on the probability redistribution, the visit detection system/model may predict speculatively that the user is visiting (or has checked into) a particular subvenue. Examples of the present disclosure further described an importance reweighting process may be used to correct the bias in data sets used to train/configure the visit detection system/model.

Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: Examples of the present disclosure describe systems and methods for passive visit detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from the set of sensors in response to detecting a movement event or user interaction data. The collected sensor data may be processed and provided as input to one or more predictive or statistical models. The model(s) may evaluate the sensor data to detect mobile device location, movement events and visit events. The model(s) may also be used to determine correlations between features of the sensor data and movement- or location-based events, optimize the types of data collected by the set of sensors, extend localized predictions to large-scale ecosystems, and generate battery-efficient state predictions. In aspects, the model(s) may be trained using labeled and/or unlabeled data sets of sensor data.

Abstract: Non-limiting examples of the present disclosure describe analysis of venue data and prediction of trendiness of venues based analyzing the venue data. As an example, one or more new venues are determined. The one or more new venues are determined by identification of a venue that has venue data existing for a period of time less than or equal to a predetermined time threshold. The venue data associated with the one or more new venues is evaluated. A predicted popularity for the one or more new venues is generated based on evaluation of the venue data. The generated predicted popularity may be provided to a processing device. In some examples, a ranked list of the one or more new venues is generated. The ranked list may display the one or more venues in a ranked order according to the generated predicted popularity. Other examples are also described.

Abstract: Adjustable devices and methods of adjusting and customizing Transcranial Magnetic Stimulation (TMS) electromagnets to produce an elongated path of induced electrical current along a user-defined trajectory in patients having a variety of different head shapes and curvatures. Existing TMS electromagnets (“coils”) allow only limited adjustment of the current delivery surfaces. The present invention provides means for adjusting the sub-coil loops within a double coil structure. The present design may be powered with the use of a single TMS pulse generator unit.

Abstract: Systems, devices and methods for applying therapeutic transcranial magnetic stimulation (TMS) to at least one superficial cortical target brain region and at least one deep brain target so that the induced current points between the superficial cortical and deep brain targets. Systems may include two TMS electromagnets configured for treating a patient by stimulating at least one deep brain region with one TMS magnet at the same time that a second TMS magnet stimulates at least one superficial cortical brain region. Also described are positioners to secure at least two TMS magnets in a substantially fixed arrangement relative to the patient's head, while allowing for fine adjustment of position and orientation of each of the TMS magnets individually to conform them to the shape of the contact surface of the body and to direct the vector direction of the overall induced current from the magnets.

Abstract: A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome.

Abstract: The invention provides lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.

Abstract: The invention provides a method for delivery iron to an animal. This invention further provides a method for treating iron deficiency in an animal.

Abstract: The invention provides lipid-based dispersion comprising comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.

Abstract: A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome.

Abstract: A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading, residual acid is quenched with a quenching agent that is base permeable at low temperatures. The residual aciditiy is thus reduced and chemical stability (e.g. against hydrolysis) is enhanced. The stability of both the liposome and the pharmaceutical agent is thus maintained, prior to administration. The pH gradient is, however, present when the liposome is administered in vivo because the quenching agent rapidly exits the liposome.